Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

被引：107

作者：

Chen, Robert ^{[1
]}

Palmer, Joycelynne M. ^{[2
]}

Thomas, Sandra H. ^{[1
]}

Tsai, Ni-Chun ^{[2
]}

Farol, Len ^{[3
]}

Nademanee, Auayporn ^{[1
]}

Forman, Stephen J. ^{[1
]}

Gopal, Ajay K. ^{[4
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol HCT, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Div Biostat, Duarte, CA 91010 USA

[3] City Hope Kaiser Permanente, Los Angeles, CA USA

[4] Univ Washington, Fred Hutchinson Canc Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA

来源：

BLOOD | 2012年 / 119卷 / 26期

基金：

美国国家卫生研究院;

关键词：

RECEPTOR;

D O I：

10.1182/blood-2012-03-418673

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Brentuximab vedotin induces an overall response rate of 75% in patients with relapsed/refractory Hodgkin lymphoma, but its impact on future allogeneic transplantation (allo-HCT) is not known. We retrospectively examined the records of 18 patients with relapsed/refractory Hodgkin lymphoma who were treated on brentuximab vedotin clinical trials to evaluate the efficacy and safety of subsequent reduced-intensity allo-HCT. Seventeen patients had previous autologous transplant; 6 were in complete remission, and 8 were in partial remission before allo-HCT with 12 grafts from unrelated or mismatched donors. The 1-year overall survival was 100%, progression-free survival was 92.3%, and nonrelapse mortality was 0% (median follow-up, 14 months). The incidence of acute GVHD was 27.8% and chronic GVHD was 56.3%. Brentuximab vedotin before reduced-intensity allo-HCT does not appear to adversely affect engraftment, GVHD, or survival and may provide sufficient disease control to enable reduced-intensity allo-HCT. (Blood. 2012;119(26):6379-6381)

引用

页码：6379 / 6381

页数：3

共 16 条

[1]

ADCETRIS, 2011, ADCETRIS PACK INS

[2] Fludarabine-meiphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience [J].

Anderlini, Paolo ;

Saliba, Rima ;

Acholonu, Sandra ;

Giralt, Sergio A. ;

Andersson, Borje ;

Ueno, Naoto T. ;

Hosing, Chitra ;

Khouri, Issa F. ;

Couriel, Daniel ;

de Lima, Marcos ;

Qazilbash, Muzaffar H. ;

Pro, Barbara ;

Romaguera, Jorge ;

Fayad, Luis ;

Hagemeister, Frederick ;

Younes, Anas ;

Munsell, Mark F. ;

Champlin, Richard E. .

HAEMATOLOGICA, 2008, 93 (02) :257-264

[3]

ANDERSON JE, 1993, BLOOD, V82, P677

[4] Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: Importance of histology for outcome [J].

Armand, Philippe ;

Kim, Haesook T. ;

Ho, Vincent T. ;

Cutler, Corey S. ;

Koreth, John ;

Antin, Joseph H. ;

LaCasce, Ann S. ;

Jacobsen, Eric D. ;

Fisher, David C. ;

Brown, Jennifer R. ;

Canellos, George P. ;

Freedman, Arnold S. ;

Soiffer, Rohert J. ;

Alyea, Edwin P. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (04) :418-425

[5] Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma [J].

Chen, Robert ;

Palmer, Joycelynne M. ;

Popplewell, Leslie ;

Shen, Jessica ;

Smith, Eileen ;

Delioukina, Maria ;

Kogut, Neil ;

Rosenthal, Joseph ;

Forman, Stephen ;

Nademanee, Auayporn .

ANNALS OF HEMATOLOGY, 2011, 90 (07) :803-808

[6]

Chen RW., 2011, J Clin Oncol, V29, P8031, DOI [10.1200/jco.2011.29.15_suppl.8031, DOI 10.1200/JCO.2011.29.15_SUPPL.8031]

[7] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[8] MOLECULAR-CLONING AND EXPRESSION OF A NEW MEMBER OF THE NERVE GROWTH-FACTOR RECEPTOR FAMILY THAT IS CHARACTERISTIC FOR HODGKINS-DISEASE [J].

DURKOP, H ;

LATZA, U ;

HUMMEL, M ;

EITELBACH, F ;

SEED, B ;

STEIN, H .

CELL, 1992, 68 (03) :421-427

[9]

FALINI B, 1995, BLOOD, V85, P1

[10]

Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO

← 1 2 →